Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
112.08
+1.68 (1.52%)
At close: Jul 14, 2026, 4:00 PM EDT
111.75
-0.33 (-0.29%)
After-hours: Jul 14, 2026, 7:28 PM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $34.37M in the quarter ending March 31, 2026, with 55.50% growth. This brings the company's revenue in the last twelve months to $51.48M, down -12.58% year-over-year. In the year 2025, Kymera Therapeutics had annual revenue of $39.21M, down -16.70%.
Revenue (ttm)
$51.48M
Revenue Growth
-12.58%
P/S Ratio
179.10
Revenue / Employee
$203,462
Employees
253
Market Cap
9.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.21M | -7.86M | -16.70% |
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
| Dec 31, 2018 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Ionis Pharmaceuticals | 1.06B |
| Corcept Therapeutics | 769.10M |
| ImmunityBio | 140.98M |
| Protagonist Therapeutics | 74.06M |
| Crinetics Pharmaceuticals | 18.07M |
| Praxis Precision Medicines | 7.46M |
KYMR News
- 1 day ago - Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital - TheFly
- 7 days ago - Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - GlobeNewsWire
- 14 days ago - Kymera Therapeutics price target raised to $125 from $110 at BofA - TheFly
- 15 days ago - Kymera Therapeutics price target raised to $155 from $117 at B. Riley - TheFly
- 15 days ago - Kymera Therapeutics price target raised to $136 from $116 at Truist - TheFly
- 18 days ago - Kymera Therapeutics price target raised to $129 from $106 at Canaccord - TheFly
- 19 days ago - Kymera Therapeutics Stock (KYMR) Soars on Accelerated Clinical Trial Enrollment - TipRanks
- 19 days ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends